semaglutide for ckd in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial FLOW trial Ozempic® (semaglutide injection)

Eli Lillys triple agonist, retatrutide, demonstrated an average weight loss of 16.8% in a Phase 3 trial for the treatment of type 2 diabetes, the company announced today

Only in rare cases are exceptions , such as when an FDA-approved drug is unavailable and only under strict regulatory conditions

DAS said the drugs are costing the state around $45 million a year

As of December 2025, retatrutide is investigational and only available through clinical trials

Ensuring that you are using the right semaglutide injection sites can improve your overall experience, making it easier to stay consistent with your medication schedule